Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
R Porta, JM Sanchez-Torres, L Paz-Ares… - European …, 2011 - Eur Respiratory Soc
Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …
[PDF][PDF] Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
R Porta, JM Sánchez-Torres, L Paz-Ares… - EUROPEAN …, 2011 - Citeseer
Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …
Brain metastases from lung cancer responding to erlotinib: The importance of EGFR mutation
R Porta, JM Sánchez-Torres… - European …, 2011 - portalrecerca.uab.cat
Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …
[PDF][PDF] Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
R Porta, JM Sánchez-Torres, L Paz-Ares… - EUROPEAN …, 2011 - researchgate.net
Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
R Porta, B Massutí, L Paz-Ares… - European …, 2010 - Eur Respiratory Soc
Median survival of patients with brain metastases from non-small-cell lung (NSCLC) cancer
is poor, and more effective treatments are urgently needed. We have evaluated the efficacy …
is poor, and more effective treatments are urgently needed. We have evaluated the efficacy …
[引用][C] Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
R PORTA, JM SANCHEZ-TORRES… - The European …, 2011 - pascal-francis.inist.fr
Author PORTA, R 1 2; SANCHEZ-TORRES, J. M 3; CATOT, S 12; ISLA, D 13; PRADAS, A 9;
GURPIDE, A 14; DE CASTRO, J 15; POLO, E 16; PUIG, T 17 2; TARON, M 18 8; COLOMER …
GURPIDE, A 14; DE CASTRO, J 15; POLO, E 16; PUIG, T 17 2; TARON, M 18 8; COLOMER …
[PDF][PDF] Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
R Porta, JM Sánchez-Torres, L Paz-Ares… - EUROPEAN …, 2011 - academia.edu
Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
R Porta, JM Sánchez-Torres… - The European …, 2011 - pubmed.ncbi.nlm.nih.gov
Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.
R Porta, JM Sánchez-Torres, L Paz-Ares… - The European …, 2010 - europepmc.org
Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …
[引用][C] Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
R Porta, JM Sanchez-Torres, L Paz-Ares… - European Respiratory …, 2010 - cir.nii.ac.jp